跳到正文
原文
MedPage Today·· 10 天前精选AI 评分65

Valbenazine 治疗 Tardive Dyskinesia 可降低抗精神病药物停药率

Valbenazine for Tardive Dyskinesia Tied to Less Antipsychotic Drop-Off

AI 导读

一项回顾性队列研究表明,使用 valbenazine 治疗 Tardive Dyskinesia 可降低新诊断患者停用所有抗精神病药物的风险(调整后的风险比 0.82)。研究者认为这有助于维持抗精神病药物的连续使用,同时直接解决 Tardive Dyskinesia。

推荐理由

研究发现,使用 valbenazine 可能有助于减少新诊断 Tardive Dyskinesia 患者的抗精神病药物停药率。

正文

— Initiation appears to have sustained psychiatric medication adherence in real-world data

November 9, 2026 • 3 min read

Starting valbenazine (Ingrezza) to treat tardive dyskinesia might reduce antipsychotic discontinuation in patients newly diagnosed with the side effect, a retrospective cohort study of Medicare claims indicated.

Among patients with schizophrenia or other psychotic spectrum disorders, valbenazine initiation was associated with an 18% lower risk of discontinuing all antipsychotics for at least 60 days (adjusted hazard ratio [aHR] 0.82, 95% CI 0.71-0.93), reported Rimal Bera, MD, of the University of California Irvine, and colleagues.

The study was presented at the Neuroscience Education Institute (NEI) Fall Congress in Colorado Springs, Colorado.

"These findings suggest that treatment of tardive dyskinesia with valbenazine may help facilitate antipsychotic continuity while directly addressing tardive dyskinesia," Bera told MedPage Today.

Part of the class of drugs dubbed VMAT2 inhibitors, valbenazine was approved in 2017 for tardive dyskinesia based on clinical trial data showing meaningful improvements on the Abnormal Involuntary Movement Scale (AIMS), which measures repetitive movements associated with the disorder.

"Keeping patients on their medications for serious mental illness is important for ongoing psychiatric stability, whereas discontinuation may increase a patient's risk of psychiatric relapse," Bera underscored.

Non-persistence to antipsychotics "may also have downstream healthcare consequences," the researchers noted on their poster. "Among patients with schizophrenia, it has been associated with increased hospitalization and emergency department use."

In the overall study cohort, which also included patients on ongoing antipsychotic therapy for mood disorders or other reasons, valbenazine initiation was not associated with a reduced risk of discontinuing all antipsychotics for at least 60 days. However, a sensitivity analysis using a 30-day or greater gap to define antipsychotic discontinuation did reach statistical significance (aHR 0.94, 95% CI 0.88-0.99), "suggesting a modestly stronger association when shorter antipsychotic coverage gaps were captured," according to the researchers.

The differences seen in the study between the overall cohort and the psychotic spectrum subgroup might reflect varying clinical needs for ongoing antipsychotic therapy, Bera suggested. "Antipsychotics are foundational to maintenance treatment for psychotic spectrum disorders, while patients with other psychiatric diagnoses, such as mood disorders, may have alternative treatment options. From a clinician's standpoint, these initial findings make sense."

He also referenced prior data from a survey of healthcare professionals that suggested valbenazine treatment might be associated with improved antipsychotic adherence.

"Real-world antipsychotic persistence and discontinuation evidence is limited, especially in the Medicare population," Bera said. "This retrospective database analysis is another method to explore real-world antipsychotic continuity ... in new tardive dyskinesia patients."

For the analysis, the researchers reviewed 100% Medicare claims from April 2016 through December 2023, identifying 66,348 eligible beneficiaries with an incident tardive dyskinesia diagnosis and active antipsychotic coverage. Beneficiaries were at least 18 years old with continuous medical and prescription drug coverage during the 365-day baseline period through the index tardive dyskinesia diagnosis. Individuals with Huntington's disease (for which valbenazine is also indicated) or baseline VMAT2 inhibitor use were excluded.

Average patient age was 62.9 years, and 60.8% were female. Most (71.2%) were eligible for both Medicare and Medicaid. More than half (52.8%) had a psychotic spectrum disorder, 38.6% had a mood disorder alone, and 8.6% had neither.

Regarding baseline antipsychotic regimens, 24.2% were on a first-generation antipsychotic, 92% on a second-generation antipsychotic, and 4.9% were on a long-acting injectable. In the baseline 365 days before the tardive dyskinesia diagnosis, 38.2% had an inpatient hospitalization and 60.9% had an emergency department visit.

During follow-up through 2023, 6,232 beneficiaries initiated valbenazine, with a median time of 36 days from tardive dyskinesia diagnosis to initiation.

The study was limited by its observational design and the potential for residual confounding, including time-varying confounding, the authors acknowledged. Claims data also do not capture clinical severity, treatment rationale, or actual medication use.

来源:MedPage Today · medpagetoday.com